Mixed allele malaria vaccines: Host protection and within-host selection

Vaccine

Volumn 26, Issue 48, 2008, Pages 6099-6107

  Barclay, Victoria C ^a,c   Chan, Brian H K ^a,c   Anders, Robin F ^b   Read, Andrew F ^a,c  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b LA TROBE UNIVERSITY   (Australia)

^c PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

AMA 1; Malaria; Strain specific immunity; Virulence

Indexed keywords

APICAL MEMBRANE ANTIGEN 1; MALARIA VACCINE; MIXED ALLELE MALARIA VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC SELECTION; GENETIC VARIABILITY; HOST SELECTION; IMMUNIZATION; MALARIA CONTROL; NONHUMAN; PARASITE VIRULENCE; PLASMODIUM CHABAUDI; PRIORITY JOURNAL; RAT;

ALLELES; ANIMALS; ANTIGENS, PROTOZOAN; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNIZATION; IMMUNOGLOBULIN G; MALARIA; MALARIA VACCINES; MEMBRANE PROTEINS; PARASITE EGG COUNT; PLASMODIUM CHABAUDI; PROTOZOAN PROTEINS; RATS; VACCINES, SYNTHETIC;

EID: 55049114441     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.09.004     Document Type: Article

References (85)

1. Richie T.L., and Saul A. Progress and challenges for malaria vaccines. Nature 415 (2002) 694-701
2. Anders R.F., Crewther P.E., Edwards S., Margetts M., Matthew M.L.S.M., Pollock B., et al. Immunisation with recombinant AMA-1 protects mice against infection with Plasmodium chabaudi. Vaccine 16 (1998) 240-247
3. Martinelli A., Cheesman S., Hunt P., Culleton P., Raza A., Mackinnon M., et al. A genetic approach to the de novo identification of targets of strain-specific immunity in malaria parasites. Proc Natl Acad Sci USA 102 (2005) 814-819
4. Cheesman S., Raza A., and Carter R. Mixed strain infections and strain-specific protective immunity in the rodent malaria parasite Plasmodium chabaudi chabaudi in mice. Infect Immun 74 (2006) 2996-3001
5. Mendis K.N., David P.H., and Carter R. Anigenic polymorphism in malaria: is it an important mechanism for immune evasion?. Immunol Today 12 (1991) A34-A37
6. Jeffery G.M. Epidemiological significance of repeated infections with homologous and heterologous starins and species of Plasmodium. WHO Bull 35 (1966) 873-882
7. Healer J., Murphy V., Hodder A.N., Masciantonio R., Gemmill A.W., Anders R.F., et al. Allelic polymorphisms in apical membrane antigen-1 are responsible for evasion of antibody-mediated inhibition in Plasmodium falciparum. Mol Microbiol 52 (2004) 159-168
8. Kennedy M.C., Wang J., Zhang Y., Miles A.P., Chitsaz F., Saul A., et al. In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. Infect Immun 70 (2002) 6948-6960
9. Saul A. Malaria vaccines based on the Plasmodium falciparum merozoite surface protein 3-should we avoid amino acid sequence polymorphisms or embrace them?. J Infect Dis 195 (2007) 171-173
10. McGregor I.A. Mechanisms of acquired immunity and epidemiological patterns of antibody response in malaria in man. Bull WHO 50 (1974) 259-266
11. McGregor I.A., Gilles H.M., Walters J.H., Davies A.H., and Pearson F.A. Effects of heavy and repeated malaria infections on Gambian infants and children; effects of erythrocytic parasitization. Br Med J 2 (1956) 686-692
12. Day K.P., and Marsh K. Naturally acquired immunity to Plasmodium falciparum. Immunol Today 12 (1991) A68-A71
13. Hodder A.N., Crewther P.E., and Anders R.F. Specificity of the protective antibody response to apical membrane antigen 1. Infect Immun 69 (2001) 3286-3294
14. Genton B., and Reed Z.H. Asexual blood-stage malaria vaccine development: facing the challenges. Curr Opin Infect Dis 20 (2007) 467-475
15. Fluck C., Smith T., Beck H.-P., Irion A., Betuela I., Alpers M.P., et al. Strain-specific humoral response to a polymorphic malaria vaccine. Infect Immun 72 (2004) 6300-6305
16. Genton B., Anders R.F., Alpers M.P., and Reeder J.C. The malaria vaccine development program in Papua New Guinea. Trends Parasitol 19 (2003) 264-270
17. Bolad A., and Berzins K. Antigenic diversity of Plasmodium falciparum and antibody-mediated parasite neutralization. Scand J Immunol 52 (2000) 233-239
18. Hoffmann S.L., and Miller L.H. In: Hoffman S.L. (Ed). Malaria Vaccine Development: a multi-immune response approach (1996), American Society for Microbiology, Washington, DC 35-76
19. Polley S., Tetteh K.A., Lloyd J., Akpogheneta O., Greenwood B., Bojang K., et al. Plasmodium falciparum merozoite surface protein 3 is a target of allele specific immunity and alleles are maintained by natural selection. J Infect Dis 195 (2007) 279-287
20. Gandon S., Mackinnon M.J., Nee S., and Read A.F. Imperfect vaccines and the evolution of pathogen virulence. Nature 414 (2001) 751-756
21. Gandon S., and Day T. Understanding and managing pathogen evolution: a way forward. Trends Microbiol 11 (2003) 206-207
22. Restif G., and Grenfell B.T. Integrating life-history and cross-immunity into the evolutionary dynamics of pathogens. Proc R Soc Lond B Biol Sci 273 (2006) 409-416
23. Gandon S., and Day T. The evolutionary epidemiology of vaccination. J R Soc Int 4 (2007) 803-817
24. André J.B., and Gandon S. Vaccination, within-host dynamics, and virulence evolution. Evolution 60 (2006) 13-23
25. Williams P.D., and Day T. Epidemiological and evolutionary consequences of targeted vaccination. Mol Ecol 17 (2008) 485-499
26. Read A.F., and Mackinnon M.J. Pathogen evolution in a vaccinated world. In: Stearns S.C., and Koella J.C. (Eds). Evolution in health and disease. 2nd ed. (2008), Oxford University Press 139-152
27. Mackinnon M.J., Gandon S., and Read A.F. Virulence evolution in response to vaccination: the case of malaria. Vaccine 26 (2008) C42-C52
28. Mackinnon M., and Read A.F. Immunity promotes virulence evolution in a malaria model. PLoS Biol 2 (2004) 1-7
29. Genton B., Betuela I., Felger I., Al-Yaman F., Anders R.F., Saul A., et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis 185 (2002) 820-827
30. Engelbrecht F., Felger I., Genton B., Alpers M., and Beck H.P. Plasmodium falciparum: malaria morbidity is associated with specific merozoite surface antigen 2 genotypes. Exp Parasitol 81 (1995) 90-96
31. Fluck C., Schopflin S., Smith T., Genton B., Alpers M.P., Beck H.-P., et al. Effect of the malaria vaccine Combination B on merozoite surface antigen 2 diversity. Infect Genet Evol 7 (2007) 44-51
32. Cowman A.F., and Crabb B.S. Invasion of red blood cells by malaria parasites. Cell 124 (2006) 755-766
33. Collins W.E., Pye D., Crewther P.E., Vandenberg K.L., Galland G.G., Sulzer A.J., et al. Protective immunity induced in squirrel monkeys with recombinant apical membrane antigen-1 of Plasmodium fragile. Am J Trop Med Hyg 51 (1994) 711-719
34. Crewther P.E., Matthew M.L., Flegg R.H., and Anders R.F. Protective immune responses to apical membrane antigen 1 of Plasmodium chabaudi involve recognition of strain-specific epitopes. Infect Immun 64 (1996) 3310-3317
35. Deans J.A., Knight A.M., Jean W.C., Waters A.P., Cohen S., and Mitchell G.H. Vaccination trials in rhesus monkeys with a minor, invariant, Plasmodium knowlesi 66 kD merozoite antigen. Parasite Immunol 10 (1988) 535-552
36. Stowers A.W., Kennedy M.C., Keegan B.P., Saul A., Long C.A., and Miller L.H. Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria. Infect Immun 70 (2002) 6961-6967
37. Kocken C.H.M., Withers-Martinez C., Dubbeld M.A., van der Wel A., Hackett F., Blackman M.J., et al. High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that Inhibit erythrocyte Invasion. Infect Immun 70 (2002) 4471-4476
38. Cortes A., Mellombo M., Masciantonio R., Murphy V.J., Reeder J.C., and Anders R.F. Allele specificity of naturally acquired antibody responses against Plasmodium falciparum apical membrane antigen 1. Infect Immun 73 (2005) 422-430
39. Johnson A.H., Leke R.G.F., Mendell N.R., Shon D., Suh Y.J., Bomba-Nkolo D., et al. Human leukocyte antigen class II alleles influence levels of antibodies to the Plasmodium falciparum asexual-stage apical membrane antigen 1 but not to merozoite surface antigen 2 and merozoite surface protein 1. Infect Immun 72 (2004) 2762-2771
40. Thomas A.W., Trape J.-F., Rogier C., Goncalves A., Rosario V.E., and Narum D.L. High prevalence of natural antibodies against Plasmodium falciparum 83-kilodalton apical membrane antigen (PF83/AMA-1) as detected by capture-enzyme-linked immunosorbent assay using full-length baculovirus recombinant PF83/AMA-1. Am J Trop Med Hyg 51 (1994) 730-740
41. Polley S.D., Mwangi T., Kocken C.H.M., Thomas A.W., Dutta S., Lanar D.E., et al. Human antibodies to recombinant protein constructs of Plasmodium falciparum apical membrane antigen 1 (AMA1) and their associations with protection from malaria. Vaccine 23 (2004) 718-728
42. Rodrigues M.H.C., Rodrigues K.M., Oliveira T.R., Cômodo A.N., Rodrigues M.M., Kocken C.H.M., et al. Antibody response of naturally infected individuals to recombinant Plasmodium vivax apical membrane antigen-1. Int J Parasitol 35 (2005) 185-192
43. Polhemus M.E., Magill A.J., Cummings J.F., Kester K.E., Ockenhouse C.F., Lanar D.E., et al. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naive adults at the Walter Reed Army Institute of Research. Vaccine 25 (2007) 4203-4212
44. Thera M.A., Doumbo O.K., Coulibaly D., Diallo D.A., Kone A.K., Guindo A.B., et al. Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial. PLoS ONE 3 (2008) e1465
45. Maher B. The end of the beginning. Nature 451 (2008) 1042-1046
46. Dutta S., Lee S.Y., Batchelor A.H., and Lanar D.E. Structural basis of antigenic escape of a malaria vaccine candidate. Proc Natl Acad Sci USA 104 (2007) 12488-12493
47. Polley S.D., Chokejindachai W., and Conway D.J. Allele frequency-based analyses robustly map sequence sites under balancing selection in a malaria vaccine candidate antigen. Genetics 165 (2003) 555-561
48. Polley S.D., and Conway D.J. Strong diversifying selection on domains of the Plasmodium falciparum apical membrane antigen 1. Genetics 158 (2001) 1505-1512
49. Peterson M.G., Marshall V.M., Smythe J.A., Crewther P.E., Lew A., Silva A., et al. Integral membrane protein located in the apical complex of Plasmodium falciparum. Mol Cell Biol 9 (1989) 3151-3154
50. Marshall V.M., Zhang L., Anders R.F., and Coppel R.L. Diversity of the vaccine candidate AMA-1 of Plasmodium falciparum. Mol Biochem Parasitol 77 (1996) 109-113
51. Malkin E.M., Diemert D.J., McArthur J.H., Perreault J.R., Miles A.P., Giersing B.K., et al. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria. Infect Immun 73 (2005) 3677-3685
52. Miura K., Zhou H., Muratova O.V., Orcutt A.C., Giersing B., Miller L.H., et al. Plasmodium falciparum apical membrane antigen 1(AMA1) immunization: fine specificity of antibodies depends on species immunized. Infect Immun 75 (2007) 5827-5836
53. Lalitha P.V., Biswas S., Pillai C.R., and Saxena R.K. Immunogenicity of a recombinant malaria vaccine candidate, domain I + II of AMA-1 ectodomain, from Indian P. falciparum alleles. Vaccine 26 (2008) 4526-4535
54. Beale G.H., Walliker D., and Carter R. Genetics. In: Killick-Kendrick R., and Peters W. (Eds). Rodent malaria (1978), Academic Press, London 213-245
55. Mackinnon M.J., and Read A.F. Genetic relationships between parasite virulence and transmission in the rodent malaria Plasmodium chabaudi. Evolution 53 (1999) 689-703
56. Marshall V.M., Peterson M.G., Lew A.M., and Kemp D.J. Structure of the apical membrane antigen I (AMA-1) of Plasmodium chabaudi. Mol Biol Parasitol 37 (1989) 281-283
57. de Roode J.C., Culleton R., Bell A.S., and Read A.F. Competitive release of drug resistance following drug treatment of mixed Plasmodium chabaudi infections. Mala J 3 (2004) 33
58. Timms R., Colegrave N., Chan B.H.K., and Read A.F. The effect of parasite dose on disease severity in the rodent malaria Plasmodium chabaudi. Parasitol 123 (2001) 1-11
59. Burns Jr. J.M., Flaherty P.R., Nanavati P., and Weidanz W.P. Protection against Plasmodium chabaudi malaria induced by immunization with apical membrane antigen 1 and merozoite surface protein 1 in the absence of gamma interferon or interleukin-4. Infect Immun 72 (2004) 5605-5612
60. Bell A.S., Roode J.C., Sim D., and Read A.F. Within-host competition in genetically diverse malaria infections: parasite virulence and competitive success. Evolution 60 (2006) 1358-1371
61. Råberg L., de Roode J.C., Bell A.S., Stamou P., Gray D., and Read A.F. The role of immune-mediated apparent competition in genetically diverse malaria infections. Am Nat 168 (2006) 41-53
62. Wargo A.R., Huijben S., de Roode J.C., Shepherd J., and Read A.F. Competitive release and facilitation of drug-resistant parasites after therapeutic chemotherapy in a rodent malaria model. Proc Natl Acad Sci USA 104 (2007) 19914-19919
63. Schofield L., and Grau G.E. Immunological processes in malaria pathogenesis. Nat Rev Immunol 5 (2005) 722-735
64. Coley A.M., Gupta A., Murphy V.J., Bai T., Kim H., Anders R.F., et al. Structure of the malaria antigen AMA1 in complex with a growth-inhibitory antibody. PLoS Pathogens 3 (2007) e138
65. Eisenhut M. Immunity to blood stages of Plasmodium falciparum is dependent on a specific pattern of immunoglobulin subclass responses to multiple blood stage antigens. Med Hypotheses 69 (2007) 804-808
66. Gray J.C., Corran P.H., Mangia E., Gaunt M.W., Li Q., Tetteh K.K.A., et al. Profiling the antibody immune response against blood stage malaria vaccine candidates. Clin Chem 53 (2007) 1244-1253
67. Osier F.H.A., Fegan G., Polley S.D., Murungi L., Verra F., Tetteh K.K.A., et al. Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect Immun 76 (2008) 2240-2248
68. Grech K., Chan B.H.K., Anders R.F., and Read A.F. The impact of immunization on competition within Plasmodium infections. Evolution 62 (2008) 2359-2371
69. Mackinnon M., and Read A.F. Virulence in malaria: an evolutionary viewpoint. Phil Trans R Soc Lond B 359 (2004) 965-986
70. Garcia J.E., Puentes A., and Patarroyo M.E. Developmental biology of sporozoite-host interactions in Plasmodium falciparum malaria: Implications for vaccine design. Clin Microbiol Rev 19 (2006) 686-707
71. Heppner J.D.G., Kester K.E., Ockenhouse C.F., Tornieporth N., Ofori O., Lyon J.A., et al. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine 23 (2005) 2243-2250
72. Hu J., Chen Z., Gu J., Wan M., Shen Q., Kieny M.-P., et al. Safety and immunogenicity of a malaria vaccine, Plasmodium falciparum AMA-1/MSP-1 chimeric protein formulated in montanide ISA 720 in healthy adults. PLoS ONE 3 (2008) e1952
73. Pan W., Huang D., Zhang Q., Qu L., Zhang D., Zhang X., et al. Fusion of two malaria vaccine candidate antigens enhances product yield, immunogenicity, and antibody-mediated inhibition of parasite growth in vitro. J Immunol 172 (2004) 6167-6174
74. Burns J.J.M., Flaherty P.R., Romero M.M., and Weidanz W.P. Immunization against Plasmodium chabaudi malaria using combined formulations of apical membrane antigen-1 and merozoite surface protein-1. Vaccine 21 (2003) 1843-1852
75. Doolan D., Sedegah M., Hedstrom R.C., Hobart P., Charoenvit Y., and Hoffman S.L. Circumventing genetic restriction of protection against malaria with muligene DNA immunization: CD8+ cell-interferon gamma-, and nitric oxide-dependent immunity. J Exp Med 183 (1996) 1739-1746
76. Scorza T., Grubb K., Cambos M., Santamaria C., Malu D.T., and Spithill T.W. Vaccination with a Plasmodium chabaudi adami multivalent DNA vaccine cross-protects A/J mice against challenge with P. c. adami DK and virulent Plasmodium chabaudi chabaudi AS parasites. Int J Parasitol 38 (2008) 819-827
77. Bouharoun-Tayoun H., Oeuvray C., Lunel F., and Druilhe P. Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J Exp Med 182 (1995) 409-418
78. Bull P.C., and Marsh K. The role of antibodies to Plasmodium falciparum-infected-erythrocyte surface antigens in naturally acquired immunity to malaria. Trends Microbiol 10 (2002) 55-58
79. Doolan D.L., Aguiar J.C., Weiss W.R., Seete A., Lelgner P.L., Regis D.P., et al. Utilization of genomic sequence information to develop malaria vaccines. Exp Biol (Berl) 206 (2003) 3789-3802
80. Moorthy V.S., Good M.F., and Hill A.V.S. Malaria vaccine developments. The Lancet 363 (2004) 150-156
81. Wipasa J., Elliot S., Xu H., and Good M.F. Immunity to asexual blood-stage malaria vaccine approaches. Immunol Cell Biol 80 (2002) 401-414
82. Wipasa J., Hirunpetcharat C., Mahakunkijcharoen Y., Xu H., Elliott S., and Good M.F. Identification of T cell epitopes on the 33-kDa fragment of Plasmodium yoelii merozoite surface protein 1 and their antibody-independent protective role in immunity to blood stage malaria. J Immunol 169 (2002) 944-951
83. Doolan D.L., and Hoffman S.L. DNA-based vaccines against malaria: status and promise of the multi-stage malaria DNA vaccine operation. Int J Parasitol 31 (2001) 753-762
84. Plebanski M., Proudfoot O., Pouniotis D., Coppel R.L., Apostolopoulos V., and Flannery G. Immunogenetics and the design of Plasmodium falciparum vaccines for use in malaria-endemic populations. J Clin Investig 110 (2002) 295-301
85. Cortes A., Mellombo M., Mueller I., Benet A., Reeder J.C., and Anders R.F. Geographical structure of diversity and differences between symptomatic and asymptomatic infections for Plasmodium falciparum vaccine candidate AMA1. Infect Immun 71 (2003) 1416-1426